Abstract:The clinical benefits of current antioxidant therapy for Alzheimer's disease (AD) are limited due to their poor disease target specificity. Our long-term objective is thus to design target-specific antioxidants and better understand their pharmacological mechanisms for AD and other human diseases, based on an emerging “pharmacophore conjugation” concept for drug development. The specific hypothesis for this studyl is that amyloid-targeting antioxidants assume targeted interdictions against cerebral Aβ amyloid pathology. We have rationally designed, synthesized, and characterized a novel bifunctional antioxidant- XH2A with chemically conjugated amyloid binding (benzothiazole) and antioxidant (lipoate) moieties. We have performed in sillico, cell culture and animal studies to characterize its partial pharmacological properties. In sillico, cellular, and animal studies on XH2A indicated that: (i) XH2A molecule has only one NH group (<5 hydrogen-bond donors), two N and one O atoms (<10 hydrogen bond acceptors), MW=414 (<500). It agrees well with the general Lipinski's Rule of Five; (ii) XH2A interacts with Aβ1-40 peptide computationally and has an affinity binding constant of KD=4.43 μM toward monomeric Aβ1-40 peptide as determined by the SPR (surface plasmon resonance) technique; (iii) XH2A has no neurotoxicity at low micromolar concentrations, and it interdicted amyloid precursor protein (APP) translation (via its 5'UTR, IC50=50 nM) in human SH-SY5Y cells and attenuated cerebral Aβ amyloid pathology in PS1/APP doubly transgenic mice without inducing apparent animal toxicity and behavior disturbances; (iv) BBB penetration studies indicated that XH2A brain concentration can reach 16 nM (via oral route, a single gavage dose of 25 mg/kg) in mouse brain in just 2 hours. This is approximately 32% of its IC50=50 nM, and its brain to plasma concentration ratio is around 1:2. XH2A interdicts Alzheimer's Aβ amyloidosis both in vitro and in vivo. Thus, XH2A could be a novel brain-permeable antioxidant targeting Alzheimer's amyloidosis.

Discovery of a novel Xanthone derivative P24 for anti-AD via targeting sTGFBR3

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Discovery of Novel Tryptanthrin Derivatives with Benzenesulfonamide Substituents as Multi-Target-Directed Ligands for the Treatment of Alzheimer's Disease

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease <i>in vitro</i> and <i>in vivo</i>

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease

Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo

A BBB-permeable Antioxidant Targeting Alzheimer's Amyloidogenesis

Design, Synthesis, and Pharmacological Characterization of Sulfonylurea-Based NLRP3 Inhibitors: Towards an Effective Therapeutic Strategy for Alzheimer's Disease

Soluble TGF-β decoy receptor TGFBR3 exacerbates Alzheimer's disease pathology by modifying microglial function

Discovery of 4-Benzylpiperazinequinoline BChE Inhibitor That Suppresses Neuroinflammation for the Treatment of Alzheimer's Disease

Multifunctional Anti-Alzheimer's Disease Effects of Natural Xanthone Derivatives: A Primary Structure-Activity Evaluation.

Discovery of Novel PDE9 Inhibitors Capable of Inhibiting Aβ Aggregation As Potential Candidates for the Treatment of Alzheimer’s Disease

Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents

Development of novel chalcone derivatives as multifunctional agents for the treatment of Alzheimer's disease

Design, synthesis, and biological evaluation of imidazolylacetophenone oxime derivatives as novel brain-penetrant agents for Alzheimer's disease treatment

Design, Synthesis, and Biological Evaluation of Imidazolylacetophenone Oxime Derivatives As Novel Brain-Penetrant Agents for Alzheimer’s Disease Treatment

Tetrahydroxy stilbene glycoside regulates TGF-β/fractalkine/CX3CR1 based on network pharmacology in APP/PS1 mouse model

Discovery of Nitazoxanide-Based Derivatives As Autophagy Activators for the Treatment of Alzheimer's Disease

A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer's disease

Synthesis and Pharmacological Evaluation of Novel Chromone Derivatives As Balanced Multifunctional Agents Against Alzheimer's Disease